PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2028 Views
-
Last post by NHE
-
- 0 Replies
- 939 Views
-
Last post by NHE
-
- 0 Replies
- 9761 Views
-
Last post by NHE
-
- 0 Replies
- 1844 Views
-
Last post by Firidion
-
- 1 Replies
- 1307 Views
-
Last post by vesta
-
- 0 Replies
- 1964 Views
-
Last post by frodo
-
- 0 Replies
- 1881 Views
-
Last post by NHE
-
- 0 Replies
- 1437 Views
-
Last post by NHE
-
- 4 Replies
- 2364 Views
-
Last post by JohnC777